Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2018: PRESS-RELEASE: Paris  July17, 2018: World's first: The French Chronic Fatigue Syndrome Association decides to clinically evaluate the ME/CFS pathogenesis model produced by Bio-Modeling Systems

  • 2018: ANNOUNCEMENT: Paris May 28, 2018 Bio-Modeling Systems est heureuse de vous informer sur ses interventions lors des conférences suivantes

  • 2018: ANNOUNCEMENT: Paris June 19-20, 2018: BMSystems invited to the Micorbiotes conference organised by Adebiotech to present its microbiota vision and CADI Discovery programs 

  • 2018: ANNOUNCEMENT: Paris June 14, 2018: BMSystems invited to the Connected Health Conference organised by ANRT to present its Real life data strategy with its "patients & HCP digital pathways" partner Bolero

  • 2018: ANNOUNCEMENT: Paris March 13-14, 2018: BMSystems invited to the Epigentic conference organised by Adebiotech to present its CADI Discovery program EPIGEN-DIAB with the Centrer of excelllence in Eipgenetic in India

  • 2017: PRESS-RELEASE: Paris-November 16, 2017: BMSystems is selected to pitch at the “Translational Neurosciences Conference” organized by “NeurATRIS” and supported by “eartis” the European Infrastructure For Translational Medicine, comprising more than 80 leading European Institutes.

  • 2017: PRESS-RELEASE: Paris-New-York October 4, 2017: BMSystems, with its 14 independently validated successes to date, is selected by the Galien Foundation for the MedStartUp Award 2017 program first step during the US Galien Prize Forum in New-York.
     
  • 2017: ANNOUNCEMENT: Latest news:  Press-release from Hospices Civils de Lyon about phage therapy success with Pherecydes Pharma bacteriophages. Pherecydes-Pharma, is BMSystems’ first therapeutic spin-off.
     

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

CADI™ Discovery - Research Production

14 CADI™ successes programs to date:

For all details download our short Presentation

  1. Mechanisms of pathogenesis & clinical progression of Creutzfeldt-Jakob Disease;
  2. Mechanisms of anti-connexin agents for modulating the therapeutic effect of psychotropic and neurodegenerative drugs;
  3. Cellular & metabolic mechanisms associated with chronic anxiety;
  4. Novel antiglycemic mechanism;
  5. Anti-metastatic mechanisms of the RGD15 peptide;
  6. Mechanisms of Ras-mediated breast cancer oncogenesis;
  7. Mechanisms of breast cancer resistance to tamoxifen;
  8. Regression mechanisms of the Müllerian duct;
  9. Mechanisms of differential melanosome degradation;
  10. Context-dependent functions of OA1 protein;
  11. Context-dependent functions OCA2 protein;
  12. Context-dependent functions SLC45A2 (MATP) protein;
  13. Engineered bacteriophage banks and the control of multi-resistant pathogens;
  14. Bioproduction and hemisynthesis of 18-methyl eicosanoic acid;

 

CADI™ programs to date in 8 domains:

  1. Infection-Immunology domain: Chronic Fatigue Syndrome; Ebola virus ecology; Hepatitis C; Auto-immune global concept
  2. Micorbiotas: Skin, lung, gut, etc, ecology, physiology & metabolic mechanisms
  3. CNS / PNS Inflammation domain: Psychiatric & neurologic treatment; Creutzfeldt-Jakob disease mechanisms; Alzheimer's Disease Mechanisms; Parkinson's Disease Treatment; Psychiatric inflammatory mechanisms; Fibromyalgia, facial pain; Pain (Central/Peripheral); Migraine Mechanisms; Multiple Sclerosis Mechanisms; Psychiatric disorders biomarkers
  4. Metabolism / Inflammation domain: Hypercholestemia Mechanisms; diabetes type 2; New global concept for Diabetes type 1; Metabolic Syndrome.
  5. Cancer / Inflammation domain: Breast cancer-Hras; Tamoxifen resistance; Specific Metastasis control; Global Metastasis control
  6. Tissue Differentiation domain: Müllerian regression Mechanisms; Adipocytes growth control
  7. Dermatology / Inflammation domain: Skin Contact Allergy Mechanisms; Skin pigmentation Mechanisms; Skin pigmentation Modulation; Skin aging Mechanisms; Modulation of skin hydration; Modulation of the lipid constituents of the skin barrier; Novel Hair Loss Mechanisms
  8. Industrial Biotech domain: Program Synthons; industrial biotech; Human Glycosylation with Yeast
     
  • Rare diseases/ Orphan diseases/ Orphan drugs based on CADI Discovery repositioning

IMPORTANT: We are not domain dependent, but smart data access dependant

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers